Track market-moving stories before they get noisy

Key Takeaways GEHC's 5 new collaborations aim to evaluate StarGuide GX's quantitative and dynamic imaging capabilities.StarGuide GX uses dsCZT detectors & NVIDIA RTX computing to enhance imaging precision & streamline workflows.GEHC's StarGuide GX holds CE Mark approval in Europe, but FDA clearance remains pending in the United States.
GE HealthCare (GEHC - Free Report) recently announced five new global clinical collaborations to evaluate its next-generation StarGuide GX digital SPECT/CT system, aimed at advancing quantitative imaging, dynamic imaging and emerging theranostics applications. The program involves leading healthcare institutions across the United States, Europe, Israel and China, with clinical insights expected to guide the future development of the company’s nuclear medicine imaging platform.

The initiative highlights GEHC’s continued focus on innovation in molecular imaging and precision medicine, particularly as theranostics gains traction in cancer diagnosis and treatment. Collaborations with established medical institutions could help strengthen clinical validation, support broader adoption of advanced imaging technologies and reinforce the company’s competitive position in nuclear medicine. However, the program’s financial contribution will depend on the pace of commercialization, regulatory clearances and eventual customer demand for StarGuide GX.

GEHC Stock Trend Following the NewsFollowing the announcement on Oct. 20, GEHC stock has traded flat till yesterday’s closing. Year to date, shares of the company have lost 15.9% compared with the industry’s 20% decline and the S&P 500’s 12.7% rise.

The global clinical evaluation program could support GEHC’s long-term growth by strengthening the clinical evidence behind its advanced molecular imaging portfolio and expanding the potential applications of the StarGuide GX platform. Feedback from leading healthcare institutions may help refine the system’s quantitative imaging capabilities, improve clinical workflows and support the development of next-generation nuclear medicine solutions. These advances could enhance GEHC’s competitive positioning in theranostics and precision oncology, where demand for technologies that help guide treatment decisions and monitor therapeutic response is growing.

GEHC currently has a market capitalization of $108.02 billion.

Image Source: Zacks Investment Research

More on the NewsGEHC StarGuide GX is a next-generation digital 4D single-photon emission computed tomography/computed tomography (SPECT/CT) system designed to advance quantitative and dynamic imaging in nuclear medicine. The platform uses dual-sided cadmium zinc telluride (dsCZT) detector technology to support high-sensitivity, high-resolution imaging and quantitative assessment. Its detector configuration allows the detectors to move closer to the patient during imaging, while the patented dual-collimator design is intended to eliminate manual external collimator exchanges and streamline workflows. These features are designed to support imaging efficiency while improving the precision of nuclear medicine assessments.

The system is engineered to accommodate radionuclides across a broad energy range, with research evaluations potentially extending to radionuclides associated with emerging alpha-emitter applications, including Actinium-225. This could help expand its potential role in theranostics, which combines diagnostic imaging with targeted treatment. In addition, NVIDIA RTX accelerated computing supports image reconstruction, while the Low-Medium Energy collimator is designed to deliver up to 2.67 times system volume sensitivity. Together, these capabilities could help clinicians obtain more detailed imaging data and support the evolving requirements of personalized medicine and advanced oncology care.

The five participating institutions will evaluate the platform according to their clinical and research priorities. Hadassah Medical Center will assess its advanced quantitative capabilities following a recent field upgrade, while Mayo Clinic will focus on quantitative and dynamic imaging applications. Oncopole Claudius Regaud in France will evaluate the system in routine oncology imaging and clinical research, Peking University First Hospital will explore novel tracer research and preclinical applications, and Rambam Health Care Campus will assess imaging workflows across a broad range of nuclear medicine applications and tracers.

The program builds on GEHC’s collaboration with University Hospital Essen in Germany, which opened a nuclear medicine center in June 2026 featuring the first installation of StarGuide GX SPECT/CT. The participating institutions have collectively conducted more than 1,000 patient scans.

StarGuide GX received CE Mark in November 2025 and is available for sale in select European Union member states. However, FDA 510(k) clearance remains pending, and the system is not currently available for sale in the United States.

Industry Prospects Favoring the MarketAccording to data provided by Mordor Intelligence, the radiopharmaceutical theranostics market size is expected to grow from $2.66 billion in 2026 to $4.46 billion by 2031 at 10.89% CAGR.

The radiopharmaceutical theranostics market is driven by rising cancer incidence, growing adoption of targeted radioligand therapies and increasing demand for precision oncology. Advances in radiopharmaceuticals, expanding clinical applications, favorable regulatory developments and investments in isotope production and nuclear medicine infrastructure are expected to support long-term market growth.

Other NewsGEHC recently announced that the MINItrace Magni cyclotron has received CE Mark certification, advancing its efforts to expand local production of radioisotopes used in positron emission tomography (“PET”) imaging. The company also expanded the PETtrace Solid Target Platform to support Copper-64 production, broadening its capabilities beyond Gallium-68 and Zirconium-89.

GEHC’s Zacks Rank & Key PicksCurrently, GEHC carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .

OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.

MMSI has an estimated long-term earnings growth rate of 10.4%. Merit Medical Systems’ earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%.

Key Takeaways GEHC's MINItrace Magni wins CE Mark, enabling local production of four radioisotopes for PET imaging.GEHC expands its PETtrace platform to support Copper-64 production, advancing radiopharmaceutical research.GEHC's expanded portfolio supports molecular imaging and theranostics across emerging cancer applications.
GE HealthCare Technologies (GEHC - Free Report) recently announced that its MINItrace Magni cyclotron has received CE Mark certification, advancing the company's efforts to expand local production of radioisotopes used in positron emission tomography (PET) imaging. The company also expanded its PETtrace Solid Target Platform to support Copper-64 production, broadening its capabilities beyond Gallium-68 and Zirconium-89. These developments strengthen GE HealthCare's molecular imaging portfolio and support emerging research into radiopharmaceuticals and theranostics.

The CE Mark enables the MINItrace Magni to support in-house production of Fluorine-18, Carbon-11, Oxygen-15 and Nitrogen-13 for PET tracers. By combining a compact, self-shielded design with automated operation, the system is intended to help healthcare institutions establish or expand local radioisotope production without requiring large-scale production infrastructure.

More on the NewsPET imaging depends on radioisotopes that can lose their usefulness quickly because of their short half-lives. Producing these products closer to healthcare facilities can improve supply planning, reduce dependence on external production and transportation, and provide greater flexibility in scheduling imaging procedures.

According to GE HealthCare, MINItrace Magni features an intuitive interface and a three-click workflow. Its automated functions include preparing the cyclotron and targets, tuning the radiation beam and managing target irradiation. The system can also be integrated with the company's TRACERcenter Solutions to support broader radiopharmacy workflows.

The PETtrace platform's addition of Copper-64 expands its solid-target capabilities beyond Gallium-68, introduced in 2022, and Zirconium-89, added in early 2026. Copper-64 is being investigated for PET imaging and in combination with Copper-67, a potential therapeutic counterpart that could enable a diagnostic-and-treatment approach known as theranostics. Research involving Copper-64-labeled compounds includes applications in prostate cancer and HER2-positive breast cancer. These applications remain under investigation.

Strategic ImplicationsThe developments reflect GE HealthCare's broader strategy of connecting imaging equipment with radioisotope production and radiopharmacy infrastructure. As molecular imaging expands across oncology, neurology and cardiology, reliable isotope availability could become increasingly important for healthcare providers. The expanded platform also offers research institutions greater flexibility to explore new radiopharmaceutical applications, although commercial benefits will depend on customer adoption and the progress of clinical research.

Industry OutlookPer a report by Precedence Research, the global radiopharmaceutical market size was valued at $7.51 billion in 2025 and is projected to grow from $8.28 billion in 2026 to $15.21 billion by 2033, at a CAGR of 7.3% from 2026 to 2033.

Demand is being driven by prostate and neuroendocrine cancer diagnosis and expansion in Asia-Pacific market. The next growth wave is likely to be driven alpha-emitting therapies, new PET tracers and earlier-line treatment expansion.

Peers in the Radiopharmaceutical SpaceOther radiopharmaceutical and theranostics companies like Lantheus , Radiopharm Theranostics and Telix Pharmaceuticals (TLX - Free Report) are also developing their product portfolio to gain from the rising demand in this space.

Lantheus strengthened its radiopharmaceutical portfolio with two notable regulatory developments in the past three months. In August 2026, the FDA approved Tauklarify, a PET imaging agent designed to detect abnormal tau protein deposits in adults with cognitive impairment being evaluated for Alzheimer’s disease.

In September, the FDA granted final approval to BRAVNETSA (lutetium Lu 177 dotatate), a radioligand therapy for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Approved through the abbreviated new drug application pathway, BRAVNETSA expands treatment options and establishes a new regulatory milestone for radioligand therapies.

Radiopharm Theranostics advanced the regulatory development of its investigational imaging agent RAD101 following an End-of-Phase 2 meeting with the FDA on Oct. 5, 2026. The discussions focused on the pivotal Phase 3 trial design for detecting suspected recurrent brain metastases after radiotherapy. RAD101 had previously demonstrated 93% concordance with MRI across evaluable lesions in its Phase 2b study, meeting the primary endpoint. The company is preparing for Phase 3 development, with formal FDA meeting minutes expected to clarify the next steps.

Telix Pharmaceuticals secured two important FDA milestones in September 2026. On Sept. 14, the FDA approved Pixclara (floretyrosine F 18), the first FDA-approved FET-PET imaging drug for glioma, helping distinguish recurrent or progressive brain tumors from treatment-related changes in adults and children aged at least one month.

On Sept. 30, Telix received Fast Track designation for its BiPASS program, which evaluates PSMA-PET imaging alongside MRI before prostate biopsy. These developments expand diagnostic applications while supporting further regulatory progress in prostate cancer imaging.

CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced LOGIQ™ Focus, a new addition to its LOGIQ family of general imaging ultrasound systems, designed to bring advanced imaging tools to a broader range of ultrasound exams. LOGIQ Focus is a versatile ultrasound system that pairs high-quality LOGIQ imaging with AI-enabled, automation and productivity tools intended to support greater confidence, consistency and efficiency across routine and more complex care areas. "As demand for imaging grows,.

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the publication of research conducted at the University of Michiganiv evaluating the use of End-tidal Control software across a large multisite academic health system in Anesthesia & Analgesia Practice. The retrospective observational study analyzed 12,818 adult general anesthesia cases performed at University of Michigan Health – Ann Arbor locations between April 1, 2023 and September 30, 2024 on anesthesia machines wit.

GE HealthCare's MINItrace™ Magni achieves CE Mark; Copper-64 expands PETtrace™ Solid Target Platform beyond Gallium-68 GE HealthCare (Nasdaq: GEHC) today announced that its MINItrace Magni cyclotron has achieved CE Mark and that its PETtrace Solid Target Platform is expanding beyond Gallium-68 with support for Copper-64 (⁶⁴Cu) production. Together, the developments reflect the company’s focus on helping institutions build the production capabilities behind their molecular imaging programs—from establishing local PET radioisotope production to supporting research into emerging radiopharmaceuticals.

For healthcare providers building or expanding a positron emission tomography (PET) program, access to tracers is an important consideration. Many PET radioisotopes have short half-lives, making proximity between production and use a factor in supply planning. Cyclotrons produce these radioisotopes, which can then be incorporated into radiotracers used in PET imaging. Local production can give providers greater control over supply and scheduling while reducing reliance on external production and transportation.

“The molecular imaging landscape is being reshaped by the expansion of theranostics, the introduction of new PET tracers, and demand across oncology, neurology and cardiology,” said Erez Levy, Vice President of Molecular Imaging at GE HealthCare. “As tracer portfolios broaden, healthcare providers need reliable access to radioisotopes and the flexibility to respond to changing clinical needs. That calls for a longer-term view of radiopharmaceutical production—one that supports established services while allowing institutions to prepare for new clinical and research applications.”

MINItrace™ Magni: supporting local production through compact design and automation
For institutions seeking to establish or expand in-house production, MINItrace Magni brings together a compact, self-shielded design and simplified operation. The cyclotron is designed to produce Fluorine-18 (¹⁸F), Carbon-11 (¹¹C), Oxygen-15 (¹⁵O) and Nitrogen-13 (¹³N) for PET tracers. Its CE Mark represents an important milestone for a system designed around the needs of in-house PET radioisotope production.

Aiming to help extend day-to-day operations, MINItrace Magni features an intuitive user interface and a three-click workflow designed to streamline routine production steps. Automated features are intended to simplify setup and operation, including auto-tuning, which prepares the cyclotron and targets, tunes the beam and manages target irradiation.

Producing the radioisotope is only one part of preparing a PET tracer. When used with GE HealthCare’s TRACERcenter Solutions, MINItrace Magni is designed to support a broader PET radiopharmacy workflow based on an institution’s clinical, operational and tracer-production needs. This approach supports providers in developing tailored local radiopharmaceutical capabilities aligned to the specific requirements of their molecular imaging programs, while considering both current and future departmental needs to create a sustainable holistic solution.

Copper-64: broadening the possibilities for PETtrace production
Alongside decisions about where to produce radioisotopes, institutions must consider which radioisotopes their programs will need. For those seeking to broaden their production capabilities, the addition of Copper-64 extends the PETtrace Solid Target Platform beyond the production of Gallium-68, for which it was introduced in 2022, and Zirconium-89, which was made available in early 2026. The capability broadens the range of isotopes that may be produced using PETtrace cyclotron infrastructure, allowing customers to build on the platform as their isotope needs evolve.

Copper-64’s relevance includes exploring its potential role in connecting imaging with investigational therapeutic applications. It enables PET imaging and is also being studied with investigational Copper-67 agents as a potential diagnostic and therapeutic pair. This research sits within the broader field of theranostics, which connects molecular imaging with targeted radionuclide therapy. Clinical research is evaluating Copper-64-labeled compounds in areas including prostate cancer and HER2-positive breast cancer.

Supporting that work involves more than the cyclotron alone. GE HealthCare’s capabilities in cyclotrons, targetry, radiochemistry synthesis, molecular imaging and services are intended to help institutions establish solid-target production as part of a broader radiopharmacy workflow.

“A molecular imaging program needs a plan for the tracers it uses today and the ones it may want to explore tomorrow,” said Nicolas Durand-Schaefer, General Manager, Molecular Imaging, International, GE HealthCare. “MINItrace Magni’s CE Mark is an important milestone for a compact, versatile cyclotron designed to support local radioisotope production and enable healthcare providers to build radiopharmacy capabilities without the need for large-scale production infrastructure. Adding Copper-64 to PETtrace broadens the platform’s capabilities to support copper-based imaging and theranostics research. Our focus is on helping institutions connect the practical demands of running a radiopharmacy with their longer-term clinical and research ambitions.”

Both developments build on more than 40 years of GE HealthCare experience in cyclotron and PET radiopharmacy technologies, extending the company’s focus on the production capabilities and workflows that support molecular imaging.

For more information about GE HealthCare’s PET radiopharmacy solutions, visit gehealthcare.com or meet with company representatives in the GE HealthCare booth at the European Association of Nuclear Medicine’s 2026 Annual Meeting, October 17-21 in Vienna, Austria.

About GE HealthCare Technologies Inc.
GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261015750771/en/

Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

-

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will announce its third quarter 2026 financial results before the market opens on Wednesday, October 28, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2026 Fortune World's Most Admired Companies™.

Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.

More News From GE HealthCare

Back to Newsroom

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027, subject to closing conditions, including regulatory approvals, at which time SOFIE Biosciences will become part of GE HealthCare’s PDx segment.

The acquisition of SOFIE Biosciences establishes a footprint for GE HealthCare in the time-critical ‘final mile’ of U.S. PET radiopharmaceutical supply, while also enabling PDx to participate in other high growth areas outside its own product portfolio. With a U.S. network of 15 CMO sites operating 21 cyclotrons, and a theranostics-focused Contract Development and Manufacturing Organization (CDMO) site, this acquisition broadens GE HealthCare's footprint in the U.S. radiopharmaceutical industry, while driving reliable patient access to novel radiopharmaceuticals. It also further enables GE HealthCare’s ability to provide solutions along every step of the theranostics pathway, from cyclotrons to imaging technology, digital workflow tools and radiotherapeutics infrastructure.

“The PET radiopharmaceutical market is expanding rapidly with the introduction of innovative radiotracers and advances in precision care, including the growing adoption of targeted therapies. As part of GE HealthCare, SOFIE Biosciences is expected to grow in the low double digits, and enables us to participate across the radiopharmaceutical value stream, meeting customer demand through a mix of GE HealthCare owned and partner facilities. SOFIE Biosciences has a highly skilled team with deep expertise serving U.S. customers, including manufacturing our Flyrcado™ (flurpiridaz F18 injection) product,” said Kevin O'Neill, President & CEO of the PDx segment at GE HealthCare. “We will leverage our scale and expertise in radiopharmaceutical manufacturing across the U.S., Europe and Japan to further invest in and grow SOFIE Biosciences, helping improve patient access, strengthen reliability of supply, and support the next generation of precision care products."

PET radiopharmaceuticals are used in precision medicine to visualize metabolic and molecular activity and, increasingly, to deliver targeted therapies across a range of disease areas. F18 labeled PET radiopharmaceuticals have a 110-minute half-life, with PET CMOs playing a crucial role in enabling timely and reliable patient access, both to existing and pipeline products. Industry-wide, the radiopharmaceutical pipeline is growing rapidly, with approximately 20 PET radiotracers and over 30 radiotherapeutics currently under development.2 These include SOFIE Biosciences’ Phase III F18 Fibroblast Activation Protein Inhibitor (FAPI) asset, FAPI-74, for which GE HealthCare already holds outside-of-U.S. rights. FAPI has the potential to further expand an already fast-growing global PET imaging market, and is showing strong potential for diagnostic and theranostic use across a range of oncologic and non-oncologic indications.

GE HealthCare will continue to drive and expand access to its existing proprietary F18 radiopharmaceutical products, while advancing its pipeline of new products, both through SOFIE Biosciences, and PDx’s other established CMO partners across the U.S.

Serving SOFIE Biosciences’ Customers

Following the transaction close, SOFIE Biosciences will continue to operate as an independent manufacturing partner to its customers, supplying its existing product portfolio, including products from other leading radiopharmaceutical providers.

Patrick Phelps, SOFIE Biosciences co-founder, President & CEO, said, “As demand continues to increase for F18 products, and pipelines for new diagnostics and therapeutics continue to expand, joining GE HealthCare marks an exciting step in our journey as a leading U.S. CMO. With Trilantic North America’s support, we have significantly expanded our capabilities and scale, and we share GE HealthCare’s ambition to improve patient outcomes by delivering on the promise of radiopharmaceuticals as we look ahead to our next phase of growth.”

Ted Rosenwasser, Partner, Trilantic North America, said, "We are incredibly proud of what Patrick and the SOFIE Biosciences team have accomplished during our partnership. SOFIE Biosciences has grown significantly, investing in its network and manufacturing capabilities to help meet growing demand and enable increased and reliable patient access to critical products. GE HealthCare's legacy and global expertise make it a natural partner to support SOFIE Biosciences’ continued growth and help expand access for U.S. patients to novel diagnostic and therapeutic radiopharmaceuticals.”

GE HealthCare’s Pharmaceutical Diagnostics segment is a global leader in imaging agents used to support 140 million procedures in 2025, equivalent to four patient procedures every second. For more than 40 years, GE HealthCare's imaging agents have been routinely used across care pathways to support diagnosis.

Financial Benefits

GE HealthCare estimates that the transaction will be accretive to revenue growth, Adjusted earnings before interest and taxes margin* and Adjusted earnings per share* in the first full year of ownership.

Advisors

For GE HealthCare, BofA Securities, Consello Financial LLC and Solomon Partners Securities LLC served as financial advisors.

Forward-Looking Statements

This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the transaction, the completion and expected results of the transaction including the financial performance of the business, industry positioning, and GE HealthCare Technologies Inc.’s (“the Company’s”) business, products, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the conditions to the completion of the transaction may not be satisfied; closing of the transaction may not occur or may be delayed; the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; the Company may assume unexpected risks and liabilities; and completing the transaction may distract the Company’s management from other important matters. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.

About SOFIE Biosciences

SOFIE Biosciences' mission is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (Theranostics). With a robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and high-value Theranostic intellectual property, SOFIE Biosciences is delivering on the promise of radiopharmaceuticals. For more information, please visit www.sofie.com or [email protected].

About Trilantic North America

Trilantic Capital Management L.P. ("Trilantic North America") is a growth-focused middle market private equity firm focused on control and significant minority investments in North America. Trilantic North America's primary investment focus is in the business and consumer services sectors. Since inception, Trilantic North America has managed seven private equity fund families, representing $11.6B in raised capital commitments. For more information, visit www.trilanticnorthamerica.com.

*Non-GAAP financial measure; see our earnings release dated July 29, 2026 for definitions.

References:

1. https://researchintelo.com/report/fapi-pet-imaging-market
2. MEDraysintell Report, 2025 Edition

The deal expands GE HealthCare's footprint in radiopharmaceuticals, its fastest-growing segment.

BENSALEM, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Happened?
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99 and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15.

During the associated earnings call, management disclosed “profit performance in the first quarter . . . was impacted by a recall associated with a PDx supplier” and that “[y]ear-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue.”

On this news, the price of GE HealthCare shares declined by $9.01 per share, or 13.2%,  to close at $59.49 per share on April 29, 2026.

On July 23, 2026, the Company announced its Chief Financial Officer, ​Jay Saccaro, will step ‌down from his role, and the Company will appoint an interim CFO while it searches for a permanent replacement.

Contact Us To Participate or Learn More:
If you purchased GE HealthCare Technologies Inc. securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: [email protected],
Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
[email protected]
www.howardsmithlaw.com

GE HealthCare Technologies (GEHC - Free Report) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.

The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.

Therefore, the Zacks rating upgrade for GE HealthCare basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.

Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for GE HealthCare imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.

Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .

Earnings Estimate Revisions for GE HealthCareThis medical technology company is expected to earn $4.93 per share for the fiscal year ending December 2026, which represents no year-over-year change.

Analysts have been steadily raising their estimates for GE HealthCare. Over the past three months, the Zacks Consensus Estimate for the company has increased 1%.

Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of GE HealthCare to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.04 per share of Common Stock for the third quarter of 2026, an increase of 14% from the previous quarter. The dividend will be payable on November 13, 2026, to all shareholders of record as of October 23, 2026. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical dia.

BENSALEM, Pa., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Happened?
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99 and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15.

During the associated earnings call, management disclosed “profit performance in the first quarter . . . was impacted by a recall associated with a PDx supplier” and that “[y]ear-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue.”

On this news, the price of GE HealthCare shares declined by $9.01 per share, or 13.2%, to close at $59.49 per share on April 29, 2026.

On July 23, 2026, the Company announced its Chief Financial Officer, ​Jay Saccaro, will step ‌down from his role, and the Company will appoint an interim CFO while it searches for a permanent replacement.

Contact Us To Participate or Learn More:
If you purchased GE HealthCare Technologies Inc. securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: [email protected],
Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
[email protected]
www.howardsmithlaw.com

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.8% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: GE HealthCare Technologies (GEHC - Free Report) Chicago, IL-based GE HealthCare Technologies, a leading global medtech company, operates across four primary segments — Imaging, Ultrasound (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Headquartered in Chicago, the company has a diversified portfolio of advanced medical imaging systems, ultrasound devices, monitoring equipment, and a growing radiopharmaceuticals pipeline. With a mission to deliver precision care, GEHC continues to pivot from a traditional equipment vendor toward an integrated solutions provider, combining hardware, software, digital analytics, and pharmaceuticals.

GEHC is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 12.98; value investors should take notice.

For fiscal 2026, six analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.04 to $4.93 per share. GEHC boasts an average earnings surprise of +0.9%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, GEHC should be on investors' short list.

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced CareIntellect™ for Operations, a new AI-enabled Software-as-a-Service (SaaS) application designed to help health systems forecast capacity constraints up to 72 hours in advance, providing comprehensive unit-, department-, and enterprise-level views of emerging bottlenecks. By analyzing hundreds of patient- and operational-level data points—including bed availability, patient delays, staffing, wait times, and ancillary services—CareIntellect for Operations predicts constraints and helps operational leaders decide what to do next by recommending prescriptive actions to optimize areas including capacity and throughput. The Queen’s Health Systems and Duke Health will be the first health systems to implement the application.

Health systems are facing rising demand, staffing shortages, and increasing costs. In 2025, inpatient volumes increased 5.3%, requiring health systems to care for more patients while operating at or near capacity.1, 2 In this environment, operational visibility and predictive insights are more important than ever. Yet leaders currently spend up to several hours each day gathering and analyzing data to answer basic operational questions, including pulling and reconciling data from multiple systems with little or no predictive foresight into oncoming bottlenecks. In some cases, teams still rely on manual processes to track operational updates and escalate issues. Even after leaders create a picture of the current state, they must then spend additional time determining how to mitigate emerging issues before they cascade into system-wide disruptions. These operational inefficiencies can create added churn for care teams, constrain patient access, and impact speed and quality of care delivery.

CareIntellect for Operations is designed to help health systems shift from reacting to operational pressure to anticipating and proactively managing resource constraints and bottlenecks. The application uses two proprietary GE HealthCare AI models. The Pressure Forecast model analyzes historical hospital operations data alongside real-time insights from the EMR and other resource management systems to predict potential resource constraints across hospitals, departments, and units up to 72 hours in advance, including census, staffing, boarding and wait times across the emergency department, therapies, procedural recovery, and inbound transfers. The Estimated Day of Discharge model analyzes longitudinal patient data to predict when individual patients are likely to be discharged, with estimates updated hourly as new information becomes available. It then surfaces recommended actions and dynamically prioritizes operational workflows to help teams address system strain and mitigate impacts to access, quality of care delivery, or capacity.

The Queen’s Health Systems and Duke Health will be the first clinical evaluation sites to implement CareIntellect for Operations, providing frontline clinical and operational feedback that GE HealthCare is using to inform future enhancements and capabilities. The application is also informed by more than two decades of healthcare operations expertise. This includes insights from its Command Center software, which is used by nearly 500 hospitals and medical facilities globally. Command Center customers have reported measurable operational outcomes, including up to $20 million in first-year cost savings,3 more than a one-day decrease in length of stay,4 and increased capacity to serve 19,000 additional patients annually.5, 6

“At Queen’s, improving access for the communities we serve is one of our top priorities, and optimizing our operations is critical to helping us achieve that,” said Alex Wroe, Chief Operating Officer at The Queen’s Medical Center. “We’ve seen firsthand how this type of advanced operational software can help us free up more capacity and better use our resources. We look forward to taking this work to the next level, helping us move beyond reacting to capacity challenges and toward proactively ensuring that our beds, teams, and resources are available for the patients who need them most.”

"Managing demand and capacity across our system in a coordinated, predictable way is essential to delivering exceptional care,” said Katie Flanagan, Associate Vice President Patient Flow and Care Coordination at Duke Health. "CareIntellect for Operations builds on three years of partnership with GE HealthCare, giving our teams a three-day view of what's coming so they can move faster from analysis to action, for the benefit of our patients.”

CareIntellect for Operations is part of GE HealthCare’s CareIntellect™ family of clinical and operational applications which share a common, cloud-first infrastructure designed to allow customers to quickly and securely onboard new CareIntellect applications without having to take a costly and time-consuming product-by-product integration approach. CareIntellect for Operations runs on Amazon Web Services (AWS) and is available for purchase directly from GE HealthCare as well as through the AWS Marketplace.

“Health systems need to know where pressure is building and what to do next. CareIntellect for Operations brings together patient and operational signals to give teams a 72-hour view of emerging constraints and help them act earlier,” said Dr. Taha Kass-Hout, Global Chief Science and Technology Officer at GE HealthCare. “AI in hospital operations has to give teams predictions they can understand, workflow-connected recommendations they can use, and a system they can trust at the point of decision—and that is the bar we designed this solution to meet.”

CareIntellect for Operations supports GE HealthCare’s strategy to deliver a new wave of innovation and further differentiate its portfolio of AI-enabled SaaS offerings that help health systems expand access, manage capacity, and keep care moving. Since 2023, GE HealthCare has invested more than $5.1 billion in innovation to elevate care, support clinicians, and streamline operations.

For more information on CareIntellect for Operations, visit: https://www.gehealthcare.com/en-us/products/software/careintellect/careintellect-for-operations?utm_source=newswire&utm_campaign=USC-USC-STO-CIO-AO-AWR-BL-26-09&utm_medium=article&utm_content=nw-press-release&utm_term=organic

Key Takeaways GE HealthCare submitted StarGuide GX for FDA 510(k) clearance after securing a CE Mark in Europe.StarGuide GX combines dual-sided CZT detectors, NVIDIA RTX computing and rapid collimator exchange.The system supports SPECT imaging and emerging tracers, including Actinium-225 and Lead-212. GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced that it is taking its next-generation StarGuide GX digital 4D cadmium zinc telluride (CZT) SPECT/CT system closer to the U.S. market with the submission to the FDA for 510(k) clearance. Following its recent CE Mark, the milestone marks continued progress toward expanding access to next-generation molecular imaging technologies and supporting a broader range of nuclear medicine applications.

Per Jean-Luc Procaccini, president and CEO, Molecular Imaging and Computed Tomography, GE HealthCare, the company is focused on innovation that anticipates the evolving needs of healthcare and provides clinicians with advanced technologies. With StarGuide GX now 510(k) pending in the United States and CE-Marked in Europe, GEHC is advancing next-generation molecular imaging solutions to support the expansion of theranostics and precision care. The technology is designed to help clinicians adopt emerging tracers, broaden clinical applications and deliver more personalized patient care.

GEHC Stock Trend Following the NewsFollowing the announcement, GEHC stock lost 3% at yesterday’s close. Year to date, shares of the company have fallen 18.6% compared with the industry’s 20.6% decline. However, the S&P 500 has risen 11.6% in the same timeframe.

The regulatory progress of StarGuide GX could strengthen GE HealthCare’s position in the growing molecular imaging market as demand for theranostics and precision medicine continues to expand. Its ability to support both general-purpose SPECT imaging and emerging tracers, including alpha emitters, could create additional opportunities for GEHC as nuclear medicine departments adopt advanced imaging technologies.

GEHC currently has a market capitalization of $31.10 billion.

Image Source: Zacks Investment Research

More on StarGuide GXStarGuide GX is designed to support the evolving theranostics landscape, where imaging plays an important role in therapy planning, dosimetry, treatment monitoring and clinical research. The system can image across a broad spectrum of energy levels, aiming to support both established SPECT applications and investigational radioligand therapy isotopes.

The system incorporates GE HealthCare’s patented dual-sided CZT detector technology, which is designed to deliver double-volume sensitivity while maintaining high-resolution imaging. The technology aims to enable clinicians to capture more information with shorter scan times. NVIDIA RTX computing is also integrated to support faster image reconstruction and accelerate time to results.

StarGuide GX features a patented dual-collimator detector designed to enable collimator exchange in less than three seconds. The automated exchange capability aims to streamline nuclear medicine workflows by reducing traditional exchange procedures and eliminating the need for multiple collimators, carts and additional storage space.

The system is particularly positioned to address growing interest in alpha-emitting isotopes such as Actinium-225 and Lead-212. As the pipeline of radioligand therapies develops, the ability to accurately image and quantify emerging tracers could become increasingly important for treatment planning, response monitoring and research.

Industry Prospects Favoring the MarketGoing by the data provided by Grand View Research, the global molecular imaging market is predicted to be valued at $9.5 billion in 2026 and is expected to witness a CAGR of 4.6% through 2030.

Factors like the increasing prevalence of cancer, cardiovascular diseases and neurological disorders, technological advancements and rising investment in research and development are boosting the market’s growth.

Other NewsGE HealthCare recently announced that its Photonova Spectra advanced photon-counting computed tomography system has received CE Mark, expanding access to the technology across Europe and other CE Mark-observing markets.

GE HealthCare also announced three additions to its Vivid cardiovascular ultrasound portfolio — Vivid Explorer, Vivid Advanced and Vivid Focus — designed to support cardiac imaging and workflow needs across different care settings.

GEHC’s Zacks Rank & Other Key PicksCurrently, GEHC carries a Zacks Rank #2 (Buy).

Some other top-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .

Veracyte, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

Globus Medical, currently sporting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced that StarGuide GX,i its new digital 4D CZT SPECT/CT technology, is 510(k) pending with the U.S. Food and Drug Administration (FDA). Building on the system's recent CE Mark, this milestone is a step towards expanding access to advanced molecular imaging technologies in the United States and marks a significant moment in molecular imaging's evolution – aiming to empower clinicians with a high-performance, general purpose scanner to help pers.

Key Takeaways GEHC's Photonova Spectra received CE Mark, expanding access across Europe and other CE markets.Deep Silicon enables ultra-high-definition imaging, spectral imaging and fast, wide-coverage scans.GEHC is collaborating with European institutions to evaluate Photonova Spectra across specialties. GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced that its Photonova Spectra advanced photon-counting computed tomography (PCCT) system has received CE Mark, expanding access to the technology across Europe and other CE Mark-observing markets. The regulatory milestone follows FDA 510(k) clearance and Japanese regulatory approval in March 2026.

Powered by GEHC’s proprietary Deep Silicon detector technology, Photonova Spectra is designed to deliver ultra-high definition imaging, on-demand spectral and spatial imaging, and fast, wide-coverage acquisition to support disease detection, characterization and monitoring.

Per management, clinicians across Europe are seeking imaging solutions that can address growing demand while enhancing diagnostic confidence. Deep Silicon photon-counting CT combines high image clarity with the efficiency required for consistent clinical use. With the CE Mark for Photonova Spectra, GE HealthCare is expanding access to the technology among European care teams, combining Deep Silicon, ultra-high-definition imaging and wide detector coverage to support fast and comprehensive acquisitions.

GEHC Stock Trend Following the NewsGEHC stock has lost 1.1% since the announcement on Monday. Year to date, the stock has fallen 14.2% compared with the industry’s 17% decline. However, the S&P 500 has risen 10.8% in the same timeframe.

The CE Mark expands GEHC’s commercial opportunity in the growing photon-counting CT market and strengthens its premium imaging portfolio. The system’s regulatory progress across the United States, Japan, Europe and other CE Mark-recognizing markets demonstrates the company’s ability to advance innovative imaging technologies. Increasing commercial opportunities, supported by clinical collaborations and strong innovation capabilities, could contribute to revenue growth and strengthen GE HealthCare’s imaging business.

GEHC currently has a market capitalization of $32.17 billion.

Image Source: Zacks Investment Research

More on Photonova SpectraA major differentiator of Photonova Spectra is its proprietary Deep Silicon detector technology, which enables precise photon energy measurement and supports advanced spectral imaging. The system provides 80 mm detector coverage and a rapid 0.23-second rotation speed, enabling fast acquisitions while improving visualization of subtle tissue variations, small lesions and vascular structures. Its one-scan, full-fidelity approach allows spectral and spatial imaging to be accessed on demand without requiring exam-specific protocols.

Using NVIDIA’s accelerated computing platform and CUDA-optimized reconstruction, the system is engineered to manage data volumes up to 50 times greater than conventional CT while delivering timely images. Automated features, including Auto Positioning and the CT ONE operator environment, further aim to improve consistency and simplify CT workflows.

Its clinical potential spans multiple specialties, including neurology, oncology, musculoskeletal, thoracic imaging and cardiology. Applications include visualization of tiny anatomical structures, lesion characterization, iodine mapping, detection of small fractures, high-detail chest imaging, and assessment of coronary stents, plaque and myocardium.

GEHC is also collaborating with UZ Brussel – Vrije Universiteit Brussel and Rigshospitalet to evaluate Photonova Spectra across cardiology, oncology, neurology, spectral imaging and musculoskeletal imaging. These collaborations could generate clinical evidence and support research into quantitative imaging, tissue characterization and spectral biomarkers, broadening the system’s clinical applications.

Industry Prospects Favoring the MarketGoing by the data provided by Business Research Insights, the global photon counting CT market is valued at $0.5 billion in 2026 and is expected to witness a CAGR of 29.4% through 2035.

Factors like regulatory approvals, strategic collaborations, rising demand for advanced diagnostic imaging and competitive innovation are boosting the market’s growth.

Other NewsGE HealthCare recently announced three additions to its Vivid cardiovascular ultrasound portfolio — Vivid Explorer, Vivid Advanced and Vivid Focus — designed to support cardiac imaging and workflow needs across different care settings.

All three new systems use cSound, a software-based imaging architecture designed to enhance contrast, resolution and tissue visualization. AI-enabled tools, including AI Auto Measure 2D, Easy AutoEF, Easy AFI LV and AI Cardiac Auto Doppler, are designed to reduce manual steps and simplify cardiac measurements.

GEHC’s Zacks Rank & Key PicksCurrently, GEHC carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) recently achieved CE Mark for Photonova Spectra,i an advanced photon-counting computed tomography (PCCT) system with the company’s proprietary Deep Silicon™ detector technology. The regulatory milestone expands access and enables clinical adoption of the technology in CE Mark–observing countries and underscores GE HealthCare’s commitment to purposeful, customer-driven innovation in computed tomography (CT).

"We are proud to deliver this new generation of photon-counting CT to the clinicians and patients around the world it was intentionally designed to serve." -- Chad Rowland, Executive Director, Global CT, GE HealthCare.

Share “We are proud to deliver this new generation of photon-counting CT to the clinicians and patients around the world it was intentionally designed to serve,” shares Chad Rowland, Executive Director, Global CT, GE HealthCare. “At its core is our Deep Silicon detector technology, which enables Photonova Spectra to capture remarkably detailed, spectral information in every scan. That level of clarity and consistency aims to make a meaningful difference in both cutting-edge research and day‑to‑day care – from helping teams see subtle findings confidently to reducing steps across a wide range of exams. Ultimately, this innovative technology was created to advance imaging as well as support the people who rely on it.”

As healthcare providers navigate rising patient volumesii and increasing diagnostic complexity,iii clinicians need clear, timely answers to inform decisions across care pathways. Photonova Spectra was intentionally engineered to help clinicians address these realities.

By harnessing the full potential of GE HealthCare’s proprietary Deep Silicon detector technology, the system’s ultra-high definition (UHD) imaging is designed to work with wide coverage, enabling fast acquisition speeds and the precise visualization of subtle tissue variations, small lesions and vascular structures. With on-demand spectral and spatial imaging for every scan and a one protocol setup for many exams, Photonova Spectra also seeks to empower clinicians to detect, characterize and monitor disease with confidence as well as reducing complexity and supporting efficiency.

“Deep Silicon brings a meaningful evolution to photon-counting CT. Silicon's unique properties as a semiconductor enables precise photon energy measurement, helping power advanced spectral imaging capabilities,” adds Johan de Mey, MD, PhD, Chair of Radiology, UZ Brussel - Vrije Universiteit Brussel. “For us, that may offer new opportunities to differentiate materials like iodine, calcium and fat, as well as provide image quality that holds up even in challenging patient scenarios. Additionally, with Photonova Spectra’s rapid 0.23‑second rotation speed and 80 mm detector coverage, we can achieve fast, motion‑free acquisitions across care areas, helping ensure that detail and diagnostic confidence aren’t compromised. These advancements aim to provide a more reliable picture of how a condition is evolving or whether a treatment is truly working, supporting more timely and informed decisions for every patient.”

The clinical potential of Photonova Spectra with Deep Silicon spans a wide range of specialties, seeking to unlock new levels of clarity, detail, and diagnostic confidence with the technology's design, including:

Neurology: Excellent visualization of tiny structures like the inner ear and clear delineation between brain grey and white matter at the same time.iv Oncology: Clear lesion characterization and precise quantification due to the system’s Deep Silicon detectors – helping clinicians make confident decisions for cancer detection. Its iodine mapping also aims to help clinicians distinguish oncological findings and support treatment monitoring. Musculoskeletal imaging: Impressive visualization of small fractures and bone marrow edema, supporting detailed assessments for orthopedic care. Thoracic imaging: Ultra-high definition chest scans, capable of revealing fine details with exceptional clarity. Cardiology: Wide coverage that provides robust imaging, while combining ultra-high definition and spectral imaging to enable in-stent lumen assessment, plaque characterization and myocardial assessment. Photonova Spectra’s advanced photon-counting architecture and Deep Silicon detector design also aim to open new possibilities for research, including quantitative imaging, tissue characterization, and spectral biomarker discovery. By enabling richer spectral data, the system may also allow researchers to explore novel clinical applications and imaging protocols that were previously constrained by conventional CT technology.

“Across Europe, clinicians are looking for imaging solutions that keep pace with rising demand while elevating diagnostic confidence,” says Catherine Estrampes, President & CEO, Global Markets, GE HealthCare. “Deep Silicon photon‑counting CT gives them both – the clarity needed to see what truly matters and the efficiency required to deliver it consistently. With CE Mark for Photonova Spectra, we’re bringing this technology to European care teams with the added strengths of Deep Silicon, ultra‑high definition imaging, and wide detector coverage to help support fast, robust acquisitions. It’s about giving clinicians tools that help them move quickly and decisively and giving their patients the reassurance that their care is guided by the best information possible.”

Photonova Spectra is intentionally designed to manage the significant data volumes generated by photon-counting CT, harnessing up to 50 times more datav than conventional CT by using NVIDIA’s accelerated computing platform and CUDA-optimized reconstruction to turn rich spectral datasets into timely, clinically actionable images while helping maintain smooth, efficient workflows.

Workflow efficiency is further supported by a one-scan, universal full fidelity approach intended to reduce exam-specific protocols and enable automated reconstruction of ultra-high definition spectral images on demand. The CT ONE operator environment and automated features – including Auto Positioning – are designed to help improve consistency across GE HealthCare systems and simplify the overall CT workflow.

Advancing innovation through global collaboration

Additionally, GE HealthCare is expanding collaborations across clinical disciplines to further evaluate Photonova Spectra and accelerate new discoveries:

UZ Brussel – Vrije Universiteit Brussel (Brussels, Belgium): A premier European academic medical center collaborating to assess the advanced capabilities of Photonova Spectra across multiple clinical domains, including cardiology, oncology, and spectral imaging. In particular, the collaboration will support the evaluation of advanced imaging applications, generating valuable clinical evidence and optimizing imaging protocols to facilitate broader adoption in routine clinical practice. Rigshospitalet (Copenhagen, Denmark): A leading university hospital for highly specialized diagnostics and treatments collaborating to explore broad the clinical applications of GE HealthCare’s photon-counting CT system. The collaboration will include a focus on low-dose imaging, enhanced tissue characterization, and the use of spectral data across complex clinical cases such as neurology, cardiology, oncology, and musculoskeletal imaging. These collaborations and the advanced architecture of Photonova Spectra could open new avenues for research in quantitative imaging, tissue characterization, and spectral biomarker development.

With CE Mark now achieved, GE HealthCare will begin commercial activities in countries that observe CE Mark.

News of Photonova Spectra’s latest regulatory achievement quickly follows its 510(k) clearance by the U.S. Food and Drug Administration (FDA) and Japanese regulatory approval in March 2026 – further demonstrating GE HealthCare’s ability to move breakthrough innovation from introduction to regulatory validation with speed and discipline.

Photonova Spectra is a result of the company’s more than $5 billion innovation investment, leading to a wave of transformational products across the portfolio which combined are expected to drive 1-2 percent revenue growth.

For more information on GE HealthCare’s new Photonova Spectra photon-counting CT with Deep Silicon detectors, please visit gehealthcare.com.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) is announcing that members of its management team will present at the following upcoming investor conference: Wells Fargo 21st Annual Health Conference – Wednesday, September 9, 2026 at 10:15 am ET/9:15am CT A webcast for the event can be accessed on the GE HealthCare website: https://investor.gehealthcare.com/news-events/events at the date and time listed above. About GE HealthCare Technologies Inc. GE HealthCare is a leading global health.

CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced three additions to its Vivid™ cardiovascular ultrasound portfolio – Vivid™ Explorer, Vivid™ Advanced and Vivid™ Focus.

It has been about a month since the last earnings report for GE HealthCare Technologies (GEHC - Free Report) . Shares have added about 3.6% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is GE HealthCare due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent catalysts for GE HealthCare Technologies Inc. before we dive into how investors and analysts have reacted as of late.

GEHC Q2 Earnings & Revenues Beat EstimatesGE HealthCare reported second-quarter 2026 adjusted earnings per share of $1.13, which beat the Zacks Consensus Estimate of $1.04 by 8.7%. The bottom line increased 6.6% year over year, aided by commercial execution, pricing and productivity gains.

GAAP EPS in the quarter was $1.24, up 16.5% from the year-ago level.

GEHC's Revenue Growth Gains MomentumRevenues of $5.29 billion increased 5.7% year over year on a reported basis and 3.5% organically. The top line surpassed the Zacks Consensus Estimate by 0.7%. Revenue growth was led by Pharmaceutical Diagnostics (PDx) and Advanced Imaging Solutions (AIS), along with strength in the United States, EMEA and Rest of World markets. However, growth was partially offset by a decline in the Patient Care Solutions (PCS) segment.

Total company orders increased 11.1% year over year organically. The book-to-bill ratio was 1.15X, indicating rising orders compared to shipments, with backlog reaching a record $23.9 billion. Management cited order growth across every segment, supported by strong commercial execution and adoption of new products.

GE HealthCare’s Q2 Segmental DetailsPharmaceutical Diagnostics revenues increased 15.6% year over year to $843 million. Growth was supported by higher contrast-media volumes, pricing and U.S. radiopharmaceutical demand. Segment EBIT was $250 million, up 16.9% year over year.

Advanced Imaging Solutions revenues increased 7.9% year over year to $3.77 billion. Growth was supported by CardioVascular and Interventional Solutions, computed tomography and Molecular Imaging. Segment EBIT was $525 million, up 15.4% year over year.

Patient Care Solutions revenues declined 13.3% year over year to $675 million. Management attributed the decline primarily to operational and fulfillment challenges, despite strong first-half orders that indicated healthy customer demand.

GEHC's Margin and Cash Flow ImproveNet income margin expanded 90 basis points to 10.6%. However, net income margin was negatively impacted due to PCS weakness and inflation in memory chips, oil and freight costs.

Cumulative cash flow from operating activities at the end of the second quarter was $458 million compared with $344 million a year ago.

GE HealthCare’s Financial PositionGEHC exited the second quarter with cash, cash equivalents and restricted cash of $2.11 billion compared with $2.28 billion in the previous quarter.

Total assets increased to $37.25 billion from $37.12 billion on a sequential basis.

GE HealthCare Reaffirms 2026 GuidanceGE HealthCare reaffirmed its guidance for 2026.

The company still expects organic revenue growth of 3-4% in 2026. It anticipates adjusted earnings per share to be in the range of $4.80-$5.00, implying 4.6%-9.0% year-over-year growth, as expected previously.

Management anticipates approximately $250 million of inflation associated with memory chips, oil and freight and other components, but expects pricing and cost actions to offset more than half of that impact.

How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a downward trend in estimates revision.

VGM ScoresCurrently, GE HealthCare has a subpar Growth Score of D, a grade with the same score on the momentum front. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, GE HealthCare has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.

Performance of an Industry PlayerGE HealthCare is part of the Zacks Medical - Products industry. Over the past month, Abbott (ABT - Free Report) , a stock from the same industry, has gained 5.7%. The company reported its results for the quarter ended June 2026 more than a month ago.

Abbott reported revenues of $12.59 billion in the last reported quarter, representing a year-over-year change of +13%. EPS of $1.31 for the same period compares with $1.26 a year ago.

Abbott is expected to post earnings of $1.43 per share for the current quarter, representing a year-over-year change of +10%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.2%.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Abbott. Also, the stock has a VGM Score of B.

Key Takeaways GEHC's Q2 organic orders rose 11.1%, with book-to-bill at 1.15X and backlog reaching a record $23.9B.GE HealthCare entered Q3 with nearly 85% of equipment revenue secured and reaffirmed 3%-4% growth.GEHC must improve PCS execution and offset about $250M of expected 2026 inflation to support margins. GE HealthCare Technologies Inc. (GEHC - Free Report) delivered a notable demand signal in the second quarter, with organic orders rising 11.1% year over year. Book-to-bill reached 1.15X and backlog climbed to a record $23.9 billion.

The key question is how much of that demand can convert into profitable revenues. Backlog visibility is improving, but execution in Patient Care Solutions and inflation remain important constraints.

GEHC’s Order Surge Was Broad BasedManagement said second-quarter order growth was broad based across every segment and included no material one-time items. The two-year order-growth stack exceeded 7%, supporting the view that demand strength extended beyond one quarter.

Orders also rose across Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions. That breadth matters because it reduces dependence on a single product category as GEHC moves through a multi-year innovation cycle.

GE HealthCare Enters Q3 With Revenue SecuredNearly 85% of equipment revenue entering the third quarter was already secured. GE HealthCare expects third-quarter organic revenue growth of 3% to 4%, providing a clearer bridge from backlog to near-term sales conversion.

The company also reaffirmed full-year organic revenue growth guidance of 3% to 4%. Execution remains the deciding factor, particularly as longer-cycle equipment orders require manufacturing, installation and customer-site readiness before they become revenues.

Image Source: Zacks Investment Research

GEHC’s Backlog Could Extend Into 2027The $23.9 billion backlog was up $2.6 billion year over year. Management said some of the strongest order growth came from longer-cycle radiology products, which are expected to contribute more meaningfully to revenues in 2027.

That timing gives GEHC visibility beyond the current year, but it also shifts attention toward conversion quality. Investors will need to watch whether backlog growth translates into sustainable revenue gains rather than simply extending delivery schedules.

GE HealthCare’s New Products Can Lift the MixPhotonova Spectra, True Definition DL and Vivid Pioneer are part of GE HealthCare’s imaging and ultrasound innovation cycle. Management said Vivid Pioneer is generating a higher gross margin than the prior platform, helped by lower manufacturing costs and AI-enabled features that support pricing.

Koninklijke Philips N.V. (PHG - Free Report) is also refreshing its imaging portfolio, including AI-powered magnetic resonance imaging and image-guided therapy technologies. Medtronic plc (MDT - Free Report) is expanding real-time AI capabilities in surgery, illustrating how product innovation and workflow productivity remain central competitive themes across medical technology.

GEHC Must Turn Orders Into Profitable RevenuePatient Care Solutions shows why strong demand alone is insufficient. Second-quarter PCS revenues declined 13.3% year over year and segment EBIT was negative, with operational and fulfillment challenges limiting backlog conversion.

Inflation adds another hurdle. GE HealthCare continues to expect about $250 million of 2026 inflation tied to memory chips, oil, freight and other components. Pricing, productivity and improved shipment velocity therefore remain important to converting backlog into margin expansion.

GEHC’s Near-Term Signal Supports the Backlog StoryGEHC’s record backlog and broad order growth improve revenue visibility, but the investment theme still depends on execution. The company must convert demand while stabilizing PCS and offsetting input-cost pressure.

GEHC currently carries a Zacks Rank #2 (Buy). Its Value Score of B is favorable for value-oriented investors, while the Growth Score of D and Momentum Score of F are weaker. The VGM Score of C reflects a mixed blend across value, growth and momentum, reinforcing the need to balance the positive near-term Rank with execution risks. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Barrow Hanley Mewhinney & Strauss LLC grew its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC – Free Report) by 13.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,455,814 shares of the company’s stock after purchasing an additional 1,571,226 shares during the period. GE HealthCare Technologies makes up 2.6% of Barrow Hanley Mewhinney & Strauss LLC’s investment portfolio, making the stock its 3rd largest position. Barrow Hanley Mewhinney & Strauss LLC owned 2.98% of GE HealthCare Technologies worth $861,307,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in GEHC. Vanguard Group Inc. lifted its position in shares of GE HealthCare Technologies by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 52,275,767 shares of the company’s stock worth $4,287,658,000 after purchasing an additional 267,058 shares in the last quarter. Auto Owners Insurance Co boosted its position in shares of GE HealthCare Technologies by 9,525.4% during the 4th quarter. Auto Owners Insurance Co now owns 33,982,610 shares of the company’s stock worth $278,725,000 after acquiring an additional 33,629,559 shares in the last quarter. Dodge & Cox increased its stake in GE HealthCare Technologies by 13.4% in the fourth quarter. Dodge & Cox now owns 31,211,229 shares of the company’s stock valued at $2,559,945,000 after purchasing an additional 3,693,918 shares during the last quarter. Capital Research Global Investors raised its stake in GE HealthCare Technologies by 1.6% during the 4th quarter. Capital Research Global Investors now owns 25,362,352 shares of the company’s stock worth $2,080,248,000 after acquiring an additional 389,796 shares in the last quarter. Finally, State Street Corp increased its position in shares of GE HealthCare Technologies by 2.0% during the fourth quarter. State Street Corp now owns 20,049,677 shares of the company’s stock worth $1,644,475,000 after purchasing an additional 401,932 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

GE HealthCare Technologies Stock Performance NASDAQ GEHC opened at $74.82 on Monday. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.26 and a quick ratio of 0.97. The company has a market cap of $33.80 billion, a P/E ratio of 17.16, a P/E/G ratio of 2.16 and a beta of 0.69. GE HealthCare Technologies Inc. has a 12 month low of $58.75 and a 12 month high of $89.77. The company has a 50-day moving average of $66.61 and a 200-day moving average of $69.53.

GE HealthCare Technologies (NASDAQ:GEHC – Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The company reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.04 by $0.09. GE HealthCare Technologies had a net margin of 9.33% and a return on equity of 20.12%. The company had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.26 billion. During the same period in the previous year, the company earned $1.06 EPS. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. As a group, equities analysts predict that GE HealthCare Technologies Inc. will post 4.93 earnings per share for the current year. GE HealthCare Technologies Dividend Announcement The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Friday, July 24th were paid a dividend of $0.035 per share. This represents a $0.14 annualized dividend and a yield of 0.2%. The ex-dividend date was Friday, July 24th. GE HealthCare Technologies’s payout ratio is currently 3.21%.

Wall Street Analyst Weigh In GEHC has been the topic of a number of recent research reports. Argus cut their target price on shares of GE HealthCare Technologies from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Royal Bank Of Canada initiated coverage on GE HealthCare Technologies in a report on Tuesday, June 23rd. They issued an “outperform” rating and a $80.00 price target for the company. UBS Group boosted their price objective on shares of GE HealthCare Technologies from $67.00 to $73.00 and gave the stock a “neutral” rating in a report on Friday, July 31st. Citigroup upped their target price on GE HealthCare Technologies from $69.00 to $75.00 and gave the company a “neutral” rating in a report on Thursday, July 30th. Finally, BMO Capital Markets initiated coverage on shares of GE HealthCare Technologies in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $70.00 price target on the stock. Ten research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat, GE HealthCare Technologies has an average rating of “Hold” and a consensus target price of $77.73.

Get Our Latest Report on GEHC

(Free Report)

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.

Read More Five stocks we like better than GE HealthCare Technologies VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Want to see what other hedge funds are holding GEHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GE HealthCare Technologies Inc. (NASDAQ:GEHC – Free Report).

Receive News & Ratings for GE HealthCare Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GE HealthCare Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

LOS ANGELES, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) investors concerning the Company’s possible violations of the federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

What Happened?
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99 and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15.

During the associated earnings call, management disclosed “profit performance in the first quarter . . . was impacted by a recall associated with a PDx supplier” and that “[y]ear-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue.”

On this news, the price of GE HealthCare shares declined by $9.01 per share, or 13.2%, to close at $59.49 per share on April 29, 2026.

On July 23, 2026, the Company announced its Chief Financial Officer, ​Jay Saccaro, will step ‌down from his role, and the Company will appoint an interim CFO while it searches for a permanent replacement.

Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

Whistleblower Notice
Persons with non-public information regarding GE HealthCare Technologies Inc. should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected].

About Glancy Prongay Wolke & Rotter LLP
Glancy Prongay Wolke & Rotter LLP (“GPWR”) is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPWR has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPWR was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements.

With four offices across the country, GPWR’s nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPWR’s lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

LOS ANGELES, Aug. 19, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of of GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ: GEHC) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON GE HEALTHCARE TECHNOLOGIES INC. (GEHC), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.  

What Is The Investigation About?
On April 29, 2026, GE HealthCare reported its financial results for the first quarter of 2026. Among other items, GE HealthCare reported adjusted earnings per share of $0.99 and cut its full-year 2026 adjusted EPS guidance to a range of $4.80 to $5.00, down from prior guidance of $4.95 to $5.15.

During the associated earnings call, management disclosed “profit performance in the first quarter . . . was impacted by a recall associated with a PDx supplier” and that “[y]ear-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue.”

On this news, the price of GE HealthCare shares declined by $9.01 per share, or 13.2%, to close at $59.49 per share on April 29, 2026.

On July 23, 2026, the Company announced its Chief Financial Officer, ​Jay Saccaro, will step ‌down from his role, and the Company will appoint an interim CFO while it searches for a permanent replacement.

Contact Us To Participate or Learn More:
If you purchased GE HealthCare Technologies Inc. securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Email us at: [email protected]
Visit our website at: www.frankcruzlaw.com.  
Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz
310-914-5007
[email protected]
www.frankcruzlaw.com